Fig. 5
Secreted extracellular PAI-1 promotes EndoMT in LECs by activating the LRP-ERK-AKT signalling pathways. A Western blotting analysis of the signalling pathways activated in PAI-1-treated HDLECs. B HDLECs transduced with siNC or siLRP1 were treated with ECM or CM for 1 h. Cell lysates were analysed by Western blotting. C The migration, tube formation and transendothelial assays were analysed following the indicated treatments. D Western blot analysis of ERK1/2 activation and the expression levels of VE-cadherin, α-SMA, FAP, and vimentin in HDLECs treated or not with PAI-1 in the presence of control or U0126 (ERK1/2 inhibitor) for 1 h. E Western blot analysis of AKT activation and the expression levels of VE-cadherin, α-SMA, FAP, and vimentin in HDLECs treated or not with PAI-1 in the presence of control or MK2206 (AKT inhibitor) for 1 h. F. The migration, tube formation and transendothelial assays were analysed following the treatments described in D. G The migration, tube formation and transendothelial assays were analysed following the treatments described in E Error bars represent the mean ± SD of three independent experiments. *, P < 0.05; **, P < 0.01